

NOTE: ▼ Limited trial; not open ETCTN-wide

ETCTN Solid Tumors, No Specified Mutations Trials (Open as of 11/10/2025)

Protocol Number	Phase	Protocol Title
10292	II	DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors
10204	lb	Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
10299	I	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
10433	I/Ib	Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors
10486	II	Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)
10499	lb/II	Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
10666	I	A Dose-Finding Phase I Study of Bone-targeted Stannic-117m Pentatate (Sn-117m-DTPA) in Solid Tumors with Skeletal Metastases
10667	Pilot	Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors